Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Dermatology

Living with CLE: Triggers, Pregnancy, and Monitoring

At a Glance

Managing Cutaneous Lupus Erythematosus (CLE) requires strictly avoiding triggers like UV light and smoking. Women planning for pregnancy should consult their doctor early to monitor autoantibody risks, while safely continuing hydroxychloroquine to protect their baby and prevent severe flares.

Living with Cutaneous Lupus Erythematosus (CLE) means becoming an expert on your own body’s triggers and your long-term health risks. While the disease primarily affects the skin, its management involves looking at the “big picture”—including lifestyle habits, reproductive health, and heart health [1][2].

Identifying and Avoiding Triggers

CLE flares are often driven by external factors that “wake up” the immune system. Identifying these early can prevent the need for more aggressive treatments.

  • Ultraviolet (UV) Light: UV rays are the most common trigger [3]. They cause skin cells to release proteins that spark an inflammatory attack [4][5]. Crucially, UV-induced flares can have a delayed onset, sometimes appearing weeks after sun exposure [3].
  • Smoking: Smoking is a major exacerbator of skin lupus [6]. It not only triggers flares but can also make hydroxychloroquine significantly less effective [3].
  • Medication Triggers: Certain common drugs can cause “drug-induced” flares, specifically the Subacute (SCLE) subtype [7]. Common culprits include proton pump inhibitors (like omeprazole for acid reflux), certain blood pressure medications, and some antifungals [8][9][7].
  • Physical Trauma: Lesions can sometimes form at sites of skin injury, including tattoos, a phenomenon known as the Koebner response [10][11].

Pregnancy and CLE: Understanding the Risks

For women with CLE, pregnancy requires extra planning, especially if they carry certain “autoantibodies” known as Anti-Ro/SSA and Anti-La/SSB [12].

  • Neonatal Lupus: These antibodies can cross the placenta. While “neonatal lupus” often just causes a temporary skin rash in the baby that clears within six months, the most serious concern is congenital heart block [13][14].
  • Heart Block Risk: This occurs in 2–5% of pregnancies where the mother has these antibodies [12]. It is a condition where the baby’s heart beats too slowly.
  • The Protective Role of Hydroxychloroquine: Hydroxychloroquine is generally considered safe during pregnancy and is highly recommended [15]. It has been shown to reduce the risk of heart block recurrence by more than 50% in high-risk pregnancies [16][17].

Important Warning: Do not stop taking hydroxychloroquine if you find out you are pregnant. Abruptly stopping medication is a leading cause of severe lupus flares. Contact your doctor immediately to discuss your care plan.

Long-Term Cardiovascular Health

Chronic inflammation from lupus—even when it is primarily in the skin—can impact the cardiovascular system over time [18].

  • Increased Risk: Patients with CLE have a higher long-term risk of heart failure, irregular heartbeats (arrhythmias), and blood clots (thromboembolic events) [18][19].
  • Proactive Screening: Because of this, it is vital to manage traditional heart risk factors more strictly than the general population. This includes regular monitoring of blood pressure, cholesterol (lipids), and blood sugar [18].

Your Long-Term Surveillance Schedule

While your doctor will tailor your schedule, a standard “maintenance” plan for CLE often includes:

  1. Skin Checks: Every 3–6 months to monitor for new activity or permanent scarring [1].
  2. Blood and Urine Labs: Every 6–12 months to check for early signs of kidney involvement or changes in blood counts [20].
  3. Eye Exams: Once a year if you are taking hydroxychloroquine to check the health of your retina [21].
  4. Heart Health Screen: Annual blood pressure and lipid checks [18].
  5. Pre-Conception Counseling: At least 3–6 months before you plan to start a family [22].

Common questions in this guide

Can I have a safe pregnancy with cutaneous lupus?
A safe pregnancy is highly possible with proper planning. If you carry Anti-Ro or Anti-La antibodies, your doctor will monitor you closely for neonatal lupus and fetal heart issues. Continuing safe medications like hydroxychloroquine is essential to protect both you and your baby.
What are the most common triggers for a cutaneous lupus flare?
Ultraviolet (UV) light from the sun is the most common trigger, and it can cause flares weeks after exposure. Smoking, physical skin trauma like tattoos, and certain medications, including proton pump inhibitors, can also trigger lupus symptoms.
Should I stop taking hydroxychloroquine if I find out I am pregnant?
No, you should not stop taking hydroxychloroquine if you become pregnant. Abruptly stopping this medication is a leading cause of severe lupus flares. It is highly recommended during pregnancy and significantly reduces the risk of fetal heart complications.
Why do I need heart health screenings if my lupus is only on my skin?
Chronic inflammation from cutaneous lupus increases your long-term risk of cardiovascular issues, such as heart failure and irregular heartbeats. Routine checks for blood pressure, cholesterol, and blood sugar are critical to catching and managing these risks early.
How often should I see my doctor for cutaneous lupus monitoring?
A standard maintenance plan includes skin checks every 3 to 6 months, blood and urine tests every 6 to 12 months, and annual heart health screenings. If you take hydroxychloroquine, you will also need a yearly eye exam to monitor your retinal health.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific antibody status for Anti-Ro/SSA and Anti-La/SSB, and what does this mean for my future pregnancy planning?
  2. 2.If I become pregnant, what is the protocol for fetal echocardiograms to monitor for heart block?
  3. 3.How often should we screen my blood pressure, cholesterol, and blood sugar given the long-term cardiovascular risks of CLE?
  4. 4.Are any of my current medications, like proton pump inhibitors or blood pressure drugs, contributing to my skin flares?
  5. 5.Can you help me create a smoking cessation plan that is tailored to my lupus management?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists.

    Childs B, Merola JF

    The Journal of clinical and aesthetic dermatology 2025; (18(10)):40-47.

    PMID: 41416023
  2. 2

    Epidemiology of cutaneous lupus erythematosus and the associated risk of systemic lupus erythematosus: a nationwide cohort study in Denmark.

    Petersen MP, Möller S, Bygum A, et al.

    Lupus 2018; (27(9)):1424-1430 doi:10.1177/0961203318777103.

    PMID: 29788808
  3. 3

    Cutaneous lupus erythematosus: clinico-pathologic correlation.

    Filotico R, Mastrandrea V

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2018; (153(2)):216-229 doi:10.23736/S0392-0488.18.05929-1.

    PMID: 29368845
  4. 4

    Understanding the Role of Type I Interferons in Cutaneous Lupus and Dermatomyositis: Toward Better Therapeutics.

    Hile GA, Werth VP

    Arthritis & rheumatology (Hoboken, N.J.) 2025; (77(1)):1-11 doi:10.1002/art.42983.

    PMID: 39262215
  5. 5

    An Overview of the Pathogenesis of Cutaneous Lupus Erythematosus.

    Verdelli A, Barletta E, Mariotti EB, et al.

    Journal of clinical medicine 2025; (14(23)) doi:10.3390/jcm14238285.

    PMID: 41375587
  6. 6

    Autoimmune Skin Conditions: Cutaneous Lupus Erythematosus.

    Foulke G, Helm LA, Clebak KT, Helm M

    FP essentials 2023; (526()):25-36.

    PMID: 36913660
  7. 7

    Amlodipine-Induced Subacute Cutaneous Lupus Erythematosus Localized to Non-Sun-Exposed Areas.

    Mizuta T, Kato M

    Case reports in dermatology 2022; (14(1)):71-76 doi:10.1159/000524001.

    PMID: 35496508
  8. 8

    Immediate and Delayed Hypersensitivity Reactions to Proton Pump Inhibitors: Evaluation and Management.

    Otani IM, Banerji A

    Current allergy and asthma reports 2016; (16(3)):17 doi:10.1007/s11882-016-0595-8.

    PMID: 26810177
  9. 9

    Proton pump inhibitors-related subacute cutaneous lupus erythematosus: Clinical characteristics, management, and outcome.

    Deng Z, Guo A, Wu C, Wang C

    Journal of cosmetic dermatology 2022; (21(12)):7202-7208 doi:10.1111/jocd.15450.

    PMID: 36214602
  10. 10

    The Koebner phenomenon on tattoos and piercings in a patient with cutaneous lupus: a case report and review of the literature.

    Kluger N, Andraud M, Lartigau-Roussin C, Sultan-Bichat N

    Acta dermatovenerologica Alpina, Pannonica, et Adriatica 2021; (30(1)):43-46.

    PMID: 33765758
  11. 11

    Discoid Lupus Erythematosus in Red Tattoo.

    Pavithran K

    Indian journal of dermatology, venereology and leprology 1983; (49(2)):82-84.

    PMID: 28176713
  12. 12

    Successful perinatal management and pacemaker stimulation during the first hour of life in a 1.6 kg newborn with autoimmune congenital complete heart block diagnosed prenatally.

    Wojtowicz A, Mroczek T, Skalski J, et al.

    Ginekologia polska 2021; (92(1)):80-81 doi:10.5603/GP.a2020.0154.

    PMID: 33576493
  13. 13

    Neonatal lupus erythematosus with congenital heart block in twins.

    Gargouri L, Safi F, Maalej B, et al.

    La Tunisie medicale 2016; (94(7)):401-404.

    PMID: 28051234
  14. 14

    Neonatal lupus erythematosus - prevention is better than cure.

    Liszewska A, Woźniacka A

    Postepy dermatologii i alergologii 2022; (39(6)):1021-1026 doi:10.5114/ada.2022.122601.

    PMID: 36686025
  15. 15

    Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study.

    Nguyen NV, Svenungsson E, Dominicus A, et al.

    Rheumatology (Oxford, England) 2025; (64(1)):117-125 doi:10.1093/rheumatology/keae168.

    PMID: 38479815
  16. 16

    Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers.

    Izmirly P, Kim M, Friedman DM, et al.

    Journal of the American College of Cardiology 2020; (76(3)):292-302 doi:10.1016/j.jacc.2020.05.045.

    PMID: 32674792
  17. 17

    Hydroxychloroquine in systemic lupus erythematosus, anti-SSA/SSB, and antiphospholipid antibody-positive pregnancies.

    Saleh ZF, Somers EC, Romero VC, Marder W

    American journal of obstetrics and gynecology 2026; (234(1)):7-20 doi:10.1016/j.ajog.2025.09.002.

    PMID: 40930382
  18. 18

    Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study.

    Shams-Eldin AN, Yafasova A, Faurschou M, et al.

    Clinical rheumatology 2022; (41(11)):3525-3536 doi:10.1007/s10067-022-06302-z.

    PMID: 35907102
  19. 19

    Cutaneous lupus erythematosus is associated with an increased risk of cardiac and vascular diseases: a large-scale, propensity-matched global retrospective cohort study.

    Olbrich H, Kridin K, Zirpel H, et al.

    EBioMedicine 2023; (93()):104639 doi:10.1016/j.ebiom.2023.104639.

    PMID: 37285617
  20. 20

    [Lupus erythematosus].

    Strunz PP, Schmalzing M, Goebeler M, Schmieder A

    Dermatologie (Heidelberg, Germany) 2025; (76(9)):582-600 doi:10.1007/s00105-025-05554-5.

    PMID: 40888883
  21. 21

    Risk of hydroxychloroquine retinopathy in the community.

    Dabit JY, Hocaoglu M, Moder KG, et al.

    Rheumatology (Oxford, England) 2022; (61(8)):3172-3179 doi:10.1093/rheumatology/keab844.

    PMID: 34788400
  22. 22

    Autoimmune Congenital Heart Block: A Review of Biomarkers and Management of Pregnancy.

    De Carolis S, Garufi C, Garufi E, et al.

    Frontiers in pediatrics 2020; (8()):607515 doi:10.3389/fped.2020.607515.

    PMID: 33415090

This page provides educational information on managing Cutaneous Lupus Erythematosus (CLE) triggers, pregnancy considerations, and long-term monitoring. It is not a substitute for professional medical advice from your dermatologist, rheumatologist, or obstetrician.

Get notified when new evidence is published on Cutaneous lupus erythematosus.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.